Advancing ADPKD clinical trials and emerging treatments
Understanding patient-centric study design and preparing sites for a changing treatment landscape are central to stronger ADPKD development programs.
Autosomal dominant polycystic kidney disease (ADPKD) can be easy to underestimate. Cysts may be enlarging and kidney function may be declining while a patient still feels well. For drug developers, this disconnect creates a central challenge: clinical trials ask people to commit to visits, monitoring, potential side effects and uncertainty before the disease feels urgent in daily life.
At the same time, the unmet need is unmistakable. Tolvaptan remains the only pharmacologic therapy approved in the United States to slow kidney function decline in adults at risk of rapidly progressing ADPKD, but it is not a cure. It can delay progression, but frequent urination, thirst and required monitoring may substantially disrupt work, school, travel and social life.
We believe this combination—silent progression and limited, burdensome treatment—makes ADPKD an especially important area for clinical development. Success, however, requires a clear understanding of how the disease presents, how patients and nephrologists make decisions and what emerging therapies will demand from sites and participants.
ADPKD may progress long before patients feel ill
Polycystic kidney disease (PKD) is the most common inherited kidney disease, affecting up to 12 million people worldwide. Approximately 90% of cases follow an autosomal dominant pattern. A disease-causing variant in one copy of PKD1 or PKD2 is sufficient to cause ADPKD, and each child of an affected parent may inherit that variant.
PKD1 is more common than PKD2, and is often associated with an earlier presentation, larger kidneys, a greater cyst burden and earlier kidney failure. Yet genotype does not tell the entire clinical story. We see meaningful variation across and within families, including patients whose initial presentation appears atypical though their estimated glomerular filtration rate later declines rapidly. That heterogeneity matters for prognosis, eligibility criteria, stratification and endpoint selection.
Many patients remain asymptomatic for years. When manifestations emerge, they may include hypertension, blood or protein in the urine, declining kidney function, flank pain, kidney stones and urinary tract infections. ADPKD is also a systemic disorder. Extrarenal manifestations may include cerebral aneurysms, liver or pancreatic cysts, cardiac valvular or aortic disease, diverticular disease, abdominal wall or inguinal hernias, and seminal vesicle cysts.
Recently diagnosed younger adults often struggle to reconcile a lifelong genetic disease with the fact that they presently feel healthy. They may be starting careers, relationships or families and feel disinclined to let ADPKD influence those life choices. Patients who have watched relatives undergo dialysis or transplantation often respond differently. They understand the possible trajectory and may be highly motivated to act early. Both perspectives are rational, and both should shape trial communication.
Diagnosis often begins with family history and imaging. Ultrasound is commonly used, while computed tomography (CT) or magnetic resonance imaging (MRI) scans may identify disease incidentally or further characterize kidney involvement. Targeted next-generation sequencing panels and whole-exome sequencing may clarify a diagnosis, particularly when imaging is atypical or family history is unknown, but access and coverage remain uneven.
Genetic testing is not simply an order placed in the patient medical record. Results may affect siblings, children, future partners and family-planning decisions. Some patients need genetic counseling before and after testing, and they need time to understand what knowing the result will mean. Pediatric screening raises similar questions. Because many children are asymptomatic, decisions about testing or imaging should reflect the potential benefits and negatives, the child’s maturity level, and the need to inform the young person of disease risk by the age of consent.
Current management focuses on controlling blood pressure, limiting dietary sodium, maintaining appropriate hydration, supporting a healthy weight and routine exercise, and treating pain or other complications. Tolvaptan may be considered for eligible patients at risk of rapid progression. As kidney disease advances, dialysis and transplantation remain kidney replacement options. This care pathway underscores why better disease-specific therapies are urgently needed.
Recruitment depends on credibility, control and a livable protocol
Lack of interest does not appear to be the defining recruitment problem in ADPKD. Many patients are eager to consider research because available options are limited, and they often want to contribute to a better future for their children and the broader PKD community. The more significant issue is whether a given ADPKD study feels credible, understandable and workable.
Credibility: Confidence earned from investigators and referring physicians
Investigators accept responsibility when they present a trial as a possible treatment option. Before opening a study, experienced nephrologists want to understand the mechanism, biological rationale, preclinical evidence, early clinical findings, safety profile and logic behind each major protocol decision. This is particularly important in Phase I and Phase II research and for genetic or other novel approaches.
A concise study synopsis is not enough. Site education should explain how the molecule is expected to affect ADPKD biology, why the population and endpoints were selected, what is known and unknown about safety, and how the protocol will affect a participant’s life. When investigators believe the evidence is robust and the study is feasible, they are more comfortable discussing it with patients.
The same principle applies to community nephrologists. Many patients receive care outside tertiary centers. As trial activity grows, referring physicians need practical education on available studies, eligibility, visit schedules, investigational mechanisms and where to send interested patients. A knowledgeable community nephrologist can normalize research as one option within a treatment plan, rather than presenting it as an unfamiliar last resort.
Control: Shared decision-making as part of retention strategy
Joining a clinical trial can be anxiety-provoking, especially for a younger patient who already knows that a genetic disorder may shape future life decisions. A patient’s trust matters, but trust alone is not informed consent. A patient should not enroll simply because a physician recommends it. The patient needs to trust the information, understand the process and decide that participation fits personal goals and circumstances.
Patients should fully understand that consent does not remove their control. They may ask questions, reconsider and withdraw. For studies involving genetic testing or genetic therapies, counseling should also address data privacy, possible implications for relatives and how results could affect family planning. Investing this time before enrollment supports better decisions and stronger retention. A participant who has deliberately chosen a study is better prepared to follow through than someone who entered because no alternative seemed available.
Livable protocols: Studies designed around real life
Treatment burden is not an abstract concept in ADPKD. Patients may have jobs that don’t allow them to have drinking water readily available or take bathroom breaks every 30 to 60 minutes. College students may feel singled out for needing frequent bathroom breaks, while travel, public transportation or workplace conditions can make intensive monitoring difficult. Their experiences with tolvaptan offer a direct lesson for investigational protocols: a regimen may be scientifically promising and still be impractical.
Before finalizing a protocol, sponsors should pressure-test with three questions:
- Can participants complete visits, laboratory testing and dosing without repeatedly sacrificing work, school or caregiving responsibilities?
- Are travel distance, local traffic, restroom access, hydration needs and route of administration reflected in feasibility planning?
- Do eligibility criteria exclude common comorbidities, such as diabetes or obesity, beyond what the scientific rationale or safety profile requires?
These questions affect both enrollment and the usefulness of the evidence. If studies systematically exclude patients with common comorbidities, the final results may not represent the population nephrologists treat. Thoughtful thresholds, multiple study options within a region and practical screening pathways expand access while preserving scientific rigor. ADPKD recruitment is often successful when the protocol respects patients’ time and produces evidence clinicians can apply.
Future therapies must improve biology and daily life
The ADPKD pipeline is expanding across several scientific directions, including approaches that address the underlying disease biology, improve prediction of progression or reduce the burden associated with current treatment. Better biomarkers are one priority. Kidney function may remain relatively stable until substantial structural change has occurred, limiting the usefulness of short-term conventional measures. Biomarkers that identify rapid progressors, track treatment response or support earlier outcome prediction could sharpen patient selection and make trials more informative. Serum proteomics-based models and imaging-derived measures are among the strategies under evaluation.
Genetic and molecular therapies may move the field closer to disease modification at its source. Research is exploring ways to increase functional polycystin production and approaches involving gene editing, CRISPR-related technologies and microRNA pathways. These strategies are scientifically compelling, but they raise additional requirements for long-term safety assessment, specialized site capabilities, clear explanations of uncertain benefit and robust protection of genetic information. The more novel the intervention, the more important transparent education becomes.
Other programs seek to improve established pathways. Next-generation vasopressin receptor antagonists will need to preserve disease-modifying potential while reducing effects such as excessive thirst and urination that interfere with daily life. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are also being studied in ADPKD, but their role is investigational and requires disease-specific evidence. Dietary strategies, including plant-based and ketogenic approaches, are generating interest as potential adjuncts—not substitutes for proven treatment.
A single answer is unlikely. ADPKD includes different genotypes, phenotypes, stages of chronic kidney disease, comorbidities and life circumstances. The future is more likely to involve multiple options matched to individual risk and preference. That diversity could improve care and make clinical-trial participation more attractive because patients and physicians would be able to compare mechanisms, administration routes, monitoring requirements and lifestyle fit.
Turning scientific momentum into meaningful options
ADPKD research has entered a period of genuine momentum. Converting that momentum into successful development programs requires alignment across medical strategy, protocol design, site education and patient engagement. Trials must be rigorous enough to earn investigator confidence and practical enough to fit into patients’ lives.
The PPD™ clinical research business of Thermo Fisher Scientific brings together renal medical expertise, global site relationships and patient-centered operational planning to address these requirements early. Our experts know that the strongest ADPKD programs involve nephrologists and patients before protocol decisions become fixed, challenge exclusions that limit real-world relevance, and treat recruitment and retention as outcomes of good design rather than downstream rescue activities.
The opportunity is larger than completing a study. It is to produce evidence clinicians can trust and therapies people can live with—so that patients have more to choose from than delaying complications with a treatment they may struggle to tolerate.
